SCHOTT Pharma AG & Co. KGaA (ETR:1SXP)
20.20
-0.15 (-0.74%)
At close: Jul 24, 2026
ETR:1SXP Balance Sheet
Financials in millions EUR. Fiscal year is October - September.
Millions EUR. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Cash & Equivalents | 27.81 | 22.47 | 23.18 | - | 28.8 |
Cash & Short-Term Investments | 27.81 | 22.47 | 23.18 | - | 28.8 |
Cash Growth | 6.60% | -3.07% | - | - | - |
Accounts Receivable | 172.41 | 201.36 | 174.89 | 71.86 | 146.43 |
Other Receivables | 165.82 | 155.1 | 141.34 | 73.92 | 161.81 |
Total Trade Receivables | 338.23 | 356.46 | 316.23 | 145.78 | 308.24 |
Inventory | 181.07 | 174.98 | 146.26 | 31.82 | 128.94 |
Other Current Assets | 122.11 | 127.5 | 98.58 | 2.61 | 88.55 |
Total Current Assets | 669.22 | 681.4 | 584.25 | 89.83 | 554.52 |
Net Property, Plant & Equipment | 804.14 | 785.67 | 723.49 | 220.2 | 517.21 |
Other Intangible Assets | 30.4 | 29.69 | 30.47 | 0.76 | 32.87 |
Long-Term Investments | 90.78 | 88.5 | 85.06 | 1,175 | 79.82 |
Other Long-Term Assets | 15.5 | 13.39 | 14.66 | - | 12.08 |
Total Assets | 1,610 | 1,599 | 1,438 | 788.53 | 1,197 |
Accounts Payable | 70.76 | 103.88 | 95.51 | 9.16 | 99.6 |
Accrued Expenses | 44.01 | 49.08 | 49.83 | - | 52.43 |
Short-Term Debt | 224.13 | 219.95 | 200.54 | - | 120.57 |
Other Current Liabilities | 82.81 | 80.94 | 89.61 | 31.02 | 50.42 |
Total Current Liabilities | 421.71 | 453.85 | 435.48 | 40.19 | 323.02 |
Long-Term Debt | 77.71 | 79.23 | 81.09 | - | 71.5 |
Other Long-Term Liabilities | 166.48 | 171.82 | 132.86 | 55.74 | 92.94 |
Total Long-Term Liabilities | 244.19 | 251.05 | 213.94 | 55.74 | 164.44 |
Total Liabilities | 665.9 | 704.9 | 649.42 | 95.93 | 487.46 |
Common Stock | 150.62 | 150.62 | 150.62 | 150.61 | 0 |
Additional Paid-in Capital | 494.48 | 494.48 | 494.48 | 491.93 | 0 |
Accumulated Other Comprehensive Income | -22.6 | -33.1 | -13.17 | - | 25.37 |
Retained Earnings | 988.96 | 279.79 | 154.71 | 50.05 | 681.91 |
Total Common Shareholders' Equity | 942.24 | 891.78 | 786.63 | 692.6 | 707.28 |
Minority Interest | 1.9 | 1.97 | 1.86 | - | 1.77 |
Shareholders' Equity | 944.14 | 893.75 | 788.49 | 692.6 | 709.04 |
Total Liabilities & Equity | 1,610 | 1,599 | 1,438 | 788.53 | 1,197 |
Total Debt | 301.84 | 299.18 | 281.62 | 0 | 192.07 |
Net Cash (Debt) | -274.03 | -276.71 | -258.44 | -0 | -163.27 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -1.82 | -1.84 | -1.72 | - | -1.08 |
Book Value | 942.24 | 891.78 | 786.63 | 692.6 | 707.28 |
Book Value Per Share | 6.25 | 5.92 | 5.22 | 4.60 | 4.70 |
Tangible Book Value | 911.84 | 862.09 | 756.16 | 691.84 | 674.41 |
Tangible Book Value Per Share | 6.04 | 5.72 | 5.02 | 4.59 | 4.48 |